Scope and Claims Analysis of US Drug Patent 12,013,403
US Drug Patent 12,013,403 is claim-focused on intrathecal bolus dosing of an 18-nucleotide antisense oligonucleotide (ASO) for spinal muscular atrophy (SMA) using a specific sequence and chemical motif, plus a defined multi-dose schedule. The claim set narrows to a single molecular species and then layers in dosing timing, route, and administration details that constrain both clinical use and potential design-arounds.
What is claimed at the core?
1) What therapeutic method is protected?
The independent claim(s) recite a method of treating SMA in a human using intrathecal bolus injection of a pharmaceutical composition containing:
- An antisense oligonucleotide of 18 linked nucleosides
- Sequence: “nucleobase sequence consisting of SEQ ID NO:1”
- Chemistry:
- Phosphorothioate internucleoside linkages (each linkage)
- 2’-MOE nucleosides (each nucleoside)
- 5-methyl cytosine (each cytosine)
Route and delivery form: “administering to the human subject by intrathecal bolus injection doses”.
Dosing: all core dose amounts are 12 mg per injection in the independent claim structure.
How broad is the molecular scope?
2) Does the patent cover a class of ASOs or a single engineered ASO?
It is effectively a single-engineered ASO scope because it locks all of the following simultaneously:
- Length: 18 nucleosides
- Sequence: SEQ ID NO:1 (exact base sequence)
- Linkage type: phosphorothioate at every internucleoside position
- Sugar: 2’-MOE at every nucleoside
- Base modification: 5-methyl cytosine at every cytosine position
That combination creates a “needle-in-haystack” claim boundary: even closely related 2’-MOE ASOs with different backbone, length, or base composition fall outside the literal claim if they do not match the defined chemical and sequence characteristics.
How broad is the dosing schedule scope?
3) What multi-dose regimen is claimed?
Claim 1 recites a six-dose regimen of 12 mg each (intrathecal bolus), with relative timing anchored to day 1 (first dose), and a minimum spacing constraint between doses 2 and 3.
| Claim 1 dosing timetable (6 doses): |
Dose # |
Dose amount |
Timing relative to first dose |
| 1 |
12 mg |
Day 0 (first dose) |
| 2 |
12 mg |
~12–18 days after dose 1 |
| 3 |
12 mg |
~25–35 days after dose 1 AND at least 14 days after dose 2 |
| 4 |
12 mg |
~60–70 days after dose 1 |
| 5 |
12 mg |
~178–188 days after dose 1 |
| 6 |
12 mg |
~298–308 days after dose 1 |
Claim 2 narrows the windows to specific “approximately” day markers (cleaner numeric embodiment):
- Dose 1: Day 0
- Dose 2: ~12 days
- Dose 3: ~25 days
- Dose 4: ~60 days
- Dose 5: ~178 days
- Dose 6: ~298 days
Claims 3 and 4 recite an alternative multi-dose regimen with fewer doses and different long-interval points.
| Claim 3 dosing timetable (5 doses) |
Dose # |
Dose amount |
Timing relative to first dose |
| 1 |
12 mg |
Day 0 |
| 2 |
12 mg |
~15 days |
| 3 |
12 mg |
~29 days |
| 4 |
12 mg |
~183 days |
| 5 |
12 mg |
~302 days |
Claim 4 adds an additional dose:
- An added 12 mg at ~64 days after dose 1, layered on top of Claim 3’s baseline schedule.
Result: the patent claims at least two different temporal embodiments of intrathecal ASO dosing in SMA, both using the same 18-mer, sequence, and chemistry.
How constrained is the route of administration?
4) What delivery requirements narrow coverage?
The independent claim requires:
- Intrathecal administration
- Bolus injection (not infusion)
- Administration is by “intrathecal bolus injection doses”
Dependent claims further tighten administration mechanics.
What do the dependent claims add?
5) What concrete procedural details are included?
Several dependent claims add technical constraints that can matter for both infringement and design-around strategy:
| Dependent claim |
Additional narrowing element |
| Claim 5 |
Administration “using a spinal anesthesia needle” |
| Claim 6 |
Administered at 2.4 mg/mL |
| Claim 7 |
Injection volume of 5.0 mL |
| Claim 8 |
Patient SMA types: I, II, III, or IV |
| Claims 9–16 |
Age bands defining when the first dose occurs (multiple < and > thresholds) |
| Claim 17 |
Patient has one or more symptoms associated with SMA |
These are not merely descriptive. They are literal claim limitations if the dependent claims are used to establish infringement under a typical “all elements” test.
Patient population scope
6) Who is covered by the treatment method?
The patent targets “a human subject in need thereof” and then adds specificity through dependent claims:
- SMA type: Claim 8 includes type I, II, III, IV
- Age at first dose: Claims 9–16 create a set of age-limited embodiments:
- Less than one week old
- Less than one month old
- Less than 3 months old
- Less than 6 months old
- Less than 1 year old
- Less than 2 years old
- Less than 15 years old
- Older than 15 years old
- Symptomatic requirement: Claim 17 requires symptoms associated with SMA
Practical reading: the dependent claims do not confine the patent to a single SMA type or a narrow pediatric cohort. They cover broad clinical categories across infancy through older childhood and adulthood, provided symptoms exist and the first-dose age falls within the claimed embodiments.
Claim architecture and enforceable “coverage islands”
7) How do claims cluster into enforceable islands?
The claim set effectively forms three overlapping layers:
-
Molecular island
- 18-mer ASO with SEQ ID NO:1
- phosphorothioate backbone
- 2’-MOE nucleosides
- 5-methyl cytosine
-
Administration island
- intrathecal bolus injection
- optional tightening via spinal anesthesia needle
-
Schedule island
- either Claim 1’s 6-dose schedule with windows
- or Claim 3’s 5-dose schedule (with optional Claim 4 dose addition)
- plus Claim 2’s explicit day values
Because the schedule is a central limitation, the patent’s practical infringement likelihood is highest when clinical protocols match the claimed timing and dose amounts.
What is the likely competitive design-around surface?
8) Which claim elements provide leverage to avoid literal infringement?
From the text provided, the most direct “escape hatches” are any changes that break an element that is both:
- explicitly defined (sequence and chemistry, route, dose amount, timing), and
- uniformly required across the independent claims.
Key elements that are rigid:
- SEQ ID NO:1
- 18 nucleosides
- phosphorothioate linkage for each internucleoside bond
- 2’-MOE for each nucleoside
- 5-methyl cytosine for each cytosine
- Intrathecal bolus delivery
- 12 mg doses at the listed relative timings (including the windows and the “at least 14 days after dose 2” constraint in Claim 1)
If a competitor’s regimen differs meaningfully in timing, route form (bolus vs infusion), dose amount, or the defined chemistry/sequence, it can fall outside literal coverage.
US patent landscape perspective (what this claim set implies)
9) Where does this patent sit in the SMA ASO ecosystem?
The claims align to the broader commercial reality that SMA is treated with intrathecal ASO technology and that dosing regimens and administration details can be separately patented. The text you provided indicates a focus on:
- a specific ASO chemistry and sequence
- a highly specific intrathecal bolus dosing pattern across months
- patient eligibility details through dependent claims
10) What adjacent patent risk usually matters for investors/R&D teams here?
Even without mapping other specific document numbers, the claim structure signals that downstream freedom-to-operate analyses commonly need to evaluate:
- whether alternative ASOs with the same target but different sequences/chemistry avoid SEQ ID NO:1 and chemical motif constraints
- whether alternative delivery modes (pump infusion vs bolus, different catheter/needle use) avoid the intrathecal bolus and needle limitations
- whether alternative schedules avoid the specific day windows and spacing requirements
- whether combination regimens or symptomatic subpopulations affect whether the dependent symptoms claim and age-embedded embodiments are triggered
Tables: consolidated claim limitations
11) Consolidated independent claim constraints (Claim 1 and Claim 3)
| Dimension |
Claim 1 |
Claim 3 |
| Route |
Intrathecal bolus injection |
Intrathecal bolus injection |
| ASO type |
18-linked nucleosides ASO |
same |
| Sequence |
SEQ ID NO:1 |
same |
| Linkage |
every linkage phosphorothioate |
same |
| Sugar |
every nucleoside 2’-MOE |
same |
| Cytosine |
5-methyl cytosine |
same |
| Dose per injection |
12 mg |
12 mg |
| Schedule |
6 doses: ~12–18d, ~25–35d (with ≥14d after dose 2), ~60–70d, ~178–188d, ~298–308d |
5 doses: ~15d, ~29d, ~183d, ~302d |
| Patient |
“human subject in need thereof” |
same |
| Additional constraints |
includes minimum spacing between dose 2 and 3 |
schedule differs |
Key Takeaways
- US 12,013,403 is an SMA intrathecal ASO method patent anchored on a single 18-nucleotide ASO defined by SEQ ID NO:1 plus exact chemistry (phosphorothioate backbone, 2’-MOE sugars, 5-methyl cytosines).
- The dosing schedule is central: Claim 1 protects a six-dose 12 mg intrathecal bolus regimen with specific timing windows and a ≥14-day spacing between dose 2 and dose 3; Claims 3 and 4 protect a separate five-dose embodiment with an optional added dose.
- Dependent claims narrow real-world practice using administrative details (spinal anesthesia needle; 2.4 mg/mL; 5.0 mL volume) and patient stratification (SMA types I–IV; multiple age-at-first-dose cutoffs; symptomatic status).
FAQs
1) Does the patent cover any 18-mer 2’-MOE antisense oligonucleotide for SMA?
No. It requires SEQ ID NO:1 and the defined phosphorothioate and 5-methyl cytosine chemistry across the molecule.
2) Is intrathecal delivery optional or strictly required?
It is strictly required: the method requires intrathecal bolus injection.
3) Are dosing timings fixed or flexible?
They are defined with specific “approximately” windows (Claim 1) and specific day markers in the narrower embodiment (Claim 2), plus relative constraints such as at least 14 days after dose 2 in Claim 1.
4) What dose amount is claimed per injection?
The claims you provided use 12 mg per dose.
5) What patient scope is covered?
Dependent claims include SMA types I–IV, multiple age at first dosing embodiments, and a symptomatic condition (symptoms associated with SMA).
References
[1] US Drug Patent 12,013,403, claims as provided by user.
